BR112022019728A2 - Polipeptídeos antifúngicos - Google Patents

Polipeptídeos antifúngicos

Info

Publication number
BR112022019728A2
BR112022019728A2 BR112022019728A BR112022019728A BR112022019728A2 BR 112022019728 A2 BR112022019728 A2 BR 112022019728A2 BR 112022019728 A BR112022019728 A BR 112022019728A BR 112022019728 A BR112022019728 A BR 112022019728A BR 112022019728 A2 BR112022019728 A2 BR 112022019728A2
Authority
BR
Brazil
Prior art keywords
amino acid
polypeptide
acid sequence
seq
nos
Prior art date
Application number
BR112022019728A
Other languages
English (en)
Inventor
Beloglazova Natalia
Adi Pierrette Revets Hilde
Stanssens Patrick
Elodie Van Daele Inge
Original Assignee
Biotalys NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotalys NV filed Critical Biotalys NV
Publication of BR112022019728A2 publication Critical patent/BR112022019728A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8282—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for fungal resistance
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
    • A01N37/46—N-acyl derivatives
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
    • A01N63/10—Animals; Substances produced thereby or obtained therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Abstract

POLIPEPTÍDEOS ANTIFÚNGICOS. A presente invenção refere-se a uma composição compreendendo pelo menos um polipeptídeo, cujo polipeptídeo compreende a sequência de aminoácidos estabelecida em qualquer uma de SEQ ID NOs: 1 a 51 ou 101 a 111 ou uma sequência de aminoácidos tendo pelo menos cerca de 80% de identidade de sequência com elas e cujo polipeptídeo é capaz de se ligar a um fungo. A invenção refere-se ainda a uma composição compreendendo pelo menos um polipeptídeo, cujo polipeptídeo compreende uma região CDR1 tendo a sequência de aminoácidos estabelecida em qualquer uma de SEQ ID NOs: 52 a 67 ou 112 a 122, uma região CDR2 tendo a sequência de aminoácidos estabelecido em qualquer uma de SEQ ID NOs: 68 a 83 ou 123 a 133, e uma região CDR3 tendo a sequência de aminoácidos estabelecida em qualquer uma de SEQ ID NOs: 84 a 100 ou 134 a 144 e cujo polipeptídeo é capaz de se ligar a um fungo. As composições podem ser usadas como composições antifúngicas.
BR112022019728A 2020-03-31 2021-03-31 Polipeptídeos antifúngicos BR112022019728A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20167432 2020-03-31
EP20218017 2020-12-31
PCT/EP2021/058548 WO2021198396A1 (en) 2020-03-31 2021-03-31 Anti-fungal polypeptides

Publications (1)

Publication Number Publication Date
BR112022019728A2 true BR112022019728A2 (pt) 2022-11-22

Family

ID=75302599

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019728A BR112022019728A2 (pt) 2020-03-31 2021-03-31 Polipeptídeos antifúngicos

Country Status (10)

Country Link
US (2) US20230110053A1 (pt)
EP (1) EP4125379A1 (pt)
JP (1) JP2023519975A (pt)
CN (1) CN115915939A (pt)
AU (1) AU2021250446A1 (pt)
BR (1) BR112022019728A2 (pt)
CA (1) CA3178461A1 (pt)
MX (1) MX2022012376A (pt)
WO (1) WO2021198396A1 (pt)
ZA (1) ZA202210882B (pt)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2294799T3 (es) 1996-06-27 2008-04-01 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Moleculas de anticuerpos que interactuan especificamente con el sitio activo o hendidura de una molecula diana.
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
WO2000002996A2 (en) 1998-07-10 2000-01-20 Cornell Research Foundation, Inc. Recombinant constructs and systems for secretion of proteins via type iii secretion systems
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
DK1144616T4 (da) 1999-01-19 2009-03-30 Unilever Nv Fremgangsmåde til fremstilling af antistoffragmenter
AP1447A (en) 1999-04-22 2005-08-12 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins.
EP1198985B1 (en) 1999-07-22 2010-09-08 National Institute Of Agrobiological Sciences Method for superrapid transformation of monocotyledon
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
ATE440111T1 (de) 1999-11-29 2009-09-15 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
EP1242460B1 (en) 1999-11-29 2006-10-18 Unilever Plc Immobilisation of proteins using a polypeptide segment
DE60138333D1 (de) 2000-03-14 2009-05-28 Unilever Nv Variabele Domänen der schweren Kette eines Antikörpers gegen menschliche Ernährungslipasen und deren Verwendungen
CA2380443C (en) 2000-05-26 2013-03-12 Ginette Dubuc Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en) 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
JP2005517674A (ja) 2002-01-03 2005-06-16 フラームス・インテルウニフェルシタイル・インステイチュート・フォール・ビオテヒノロヒー・ヴェーゼットウェー 腫瘍の処置に有用な新規免疫コンジュゲート
EP1558646A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses thereof
CA2505326A1 (en) 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
AU2008328779B2 (en) * 2007-11-27 2014-06-05 Ablynx N.V. Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
EP2315772A4 (en) 2008-08-12 2012-02-08 Plant Health Care Inc Preparation, Formulation and Use of Stable Liquid Paste Formulations
WO2010066740A1 (en) 2008-12-08 2010-06-17 Complix Nv Single-chain antiparallel coiled coil proteins
EP3597758A1 (en) 2013-04-29 2020-01-22 AgroSavfe nv Agrochemical compositions comprising polypeptides
US10858666B2 (en) * 2014-11-05 2020-12-08 Biotalys Transgenic plants expressing a variable domain of a heavy chain antibody (VHH) that binds to a sphingolipid of a fungus
EP3615082A4 (en) 2017-04-28 2021-05-26 Agrospheres, Inc. COMPOSITIONS AND PROCEDURES FOR ENZYMIMMOBILIZATION
BR112019022539A2 (pt) 2017-04-28 2020-06-16 Agrospheres, Inc. Composições e métodos para o encapsulamento e entrega escalonável de agorquímicos
BR112020005803A2 (pt) 2017-09-25 2020-12-01 Agrospheres, Inc. composições e métodos para produção e administração moduláveis de produtos biológicos
SG11202002873XA (en) * 2017-10-11 2020-04-29 Nanjing Legend Biotech Co Ltd Compositions and methods for increasing protein half-life in a serum

Also Published As

Publication number Publication date
WO2021198396A1 (en) 2021-10-07
JP2023519975A (ja) 2023-05-15
CN115915939A (zh) 2023-04-04
US20230287447A1 (en) 2023-09-14
CA3178461A1 (en) 2021-10-07
MX2022012376A (es) 2023-02-15
AU2021250446A1 (en) 2022-11-17
ZA202210882B (en) 2024-02-28
EP4125379A1 (en) 2023-02-08
US20230110053A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
BR112022016220A2 (pt) Polipeptídeos, composições e seu uso para tratar ou limitar o desenvolvimento de uma infecção
PE20220283A1 (es) Composicion farmaceutica para inyeccion subcutanea que comprende una variante de hialuronidasa humana ph20 y un medicamento
HRP20180135T1 (hr) Kimerni i hibridni polipeptidi čimbenika viii-fc, te postupci njihove upotrebe
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
BR112018003594A2 (pt) cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados
NZ606584A (en) Binding proteins for hepcidin
MY194925A (en) Composition of fish skin collagen peptides and use thereof as a drug
BR112017014559A2 (pt) polipeptídeo de ligação de il-17a, proteína de fusão ou conjugado, complexo, polinucleotídeo que codifica um polipeptídeo, e, composição
AU2020273903B2 (en) Novel modified immunoglobulin Fc-fusion protein and use thereof
MX2021013743A (es) Subunidad s1 modificada de la proteina de espicula de coronavirus.
BR112023019228A2 (pt) Peptídeo e composição contendo o peptídeo
BR122018077204B8 (pt) peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica
EA202092458A1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
BR112018012055A2 (pt) substrato de transglutaminase (tg) recombinante, método in vitro para marcar uma proteína de interesse, composição farmacêutica ou de diagnóstico e kit de diagnóstico
BR112022019728A2 (pt) Polipeptídeos antifúngicos
McMahan et al. Study of amino acid modifiers in guayule natural rubber
WO2023130022A3 (en) Cystatin rna compositions for tissue engineering
MX2020010422A (es) Alfa-amilasa maltogenica variante.
AR121723A1 (es) Polipéptidos antifúngicos
WO2022031733A3 (en) Keratinolytic polypeptides and methods of use
MX2022002171A (es) Dominios fc variantes y usos de estos.
BR112023005152A2 (pt) Anticorpo biespecífico com especificidade intensificada (seba)
CR20230240A (es) Composición de péptidos para inmunoterapia
MX2022012076A (es) Variante del fc y preparacion de la misma.
PL431445A1 (pl) Rekombinowany polipeptyd do zastosowania jako lek, środek antyseptyczny, środek przeciwbakteryjny, środek przeciwzapalny, kompozycje go zawierające oraz jego zastosowania

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: BIOTALYS NV (BE)